<DOC>
	<DOCNO>NCT01183364</DOCNO>
	<brief_summary>This open-label , Phase 1 , dose-escalation study determine recommend dos STA-9090 ( ganetespib ) docetaxel treatment subject solid tumor malignancy . The safety tolerability treatment also evaluate .</brief_summary>
	<brief_title>A Dose Escalation Study STA-9090 Docetaxel Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Must histologically confirm metastatic unresectable malignancy evidence progression If subject treat docetaxel , must evidence persistent progressive disease Measurable disease per RECIST CNS metastasis permit treat radiographically clinically stable 4 week prior first dose ECOG status less equal 2 Life expectancy great 3 month Adequate hematological , hepatic renal function define protocol Willingness ability comply study requirement Female subject childbearing age must negative pregnancy test study entry Female subject child bearing age male must agree use adequate contraception define protocol Prior chemotherapy investigational agent within 3 week 5 time agent 's half life , whichever short prior first dose Radiotherapy within 2 week first dose Surgery , radiotherapy ablative procedure area measurable disease Major surgery within 4 week first dose Poor venous access would require indwell catheter study drug administration History severe allergic hypersensitivity reaction STA9090 docetaxel diluent excipients Baseline QTc &gt; 470 msec previous history QT prolongation take medication Peripheral neuropathy &gt; Grade 1 Ventricular ejection fraction less equal 55 % baseline Treatment chronic immunosuppressant . However subject may receive steroid stable CNS metastasis Women pregnant lactating Uncontrolled intercurrent illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>solid tumor malignancy</keyword>
	<keyword>tumor</keyword>
	<keyword>cancer</keyword>
	<keyword>STA-9090</keyword>
	<keyword>ganetespib</keyword>
	<keyword>HSP90 inhibitor</keyword>
</DOC>